Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
SynKinase
Alpelisib
As low as
CHF 0.00
In stock
Only %1 left
SYN-1230-M0011 mgCHF 114.00
SYN-1230-M0055 mgCHF 213.00
SYN-1230-M01010 mgCHF 312.00
SYN-1230-M05050 mgCHF 1’064.00
SYN-1230-M100100 mgINQ
Specifications / Handling
| Product Details | |
|---|---|
| Synonyms | (2S)-N1-[4-Methyl-5-[2-(2,2,2-trifluoro-1,1-dimethylethyl)-4-pyridinyl]-2-thiazolyl]-1,2-pyrrolidinedicarboxamide; BYL719; NVP-BYL719 |
| Product Type | Chemical |
| Properties | |
| Formula | C19H22F3N5O2S |
| MW | 441.5 |
| CAS | 1217486-61-7 |
| Purity Chemicals | ≥95% |
| Appearance | Solid. |
| Solubility | Soluble in DMSO or DMF. |
| Declaration | Manufactured by SynKinase. |
| Other Product Data | Target: PI3Kalpha | Kinase Group: Lipid Kinase | Substrate: Lipid |
| InChi Key | STUWGJZDJHPWGZ-LBPRGKRZSA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Scientific Background Information
Product Description
Selective PI3Kα inhibitor with IC50 of 5nM. Has minimal effect on other PI3K isoforms. Exhibits favorable pharmacokinetics and excellent oral bioavailability in animal models. In xenografts using nude mice, it showed dose-dependent effects of tumour inhibition. In a phase Ib study, it showed synergistic anti-tumor activity with endocrine therapy against ER+/PIK3CA mutated breast cancer cells.
Product-specific References
- Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation: P. Furet, et al.; Bioorg. Med. Chem. Lett. 23, 3741 (2013)
- Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials: C. Fritsch, et al.; Mol. Cancer Ther. 13, 1117 (2014)
- A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-specific Inhibitor, with Letrozole in ER+/HER2-Negative Metastatic Breast Cancer: I.A. Mayer, et al.; Clin. Cancer Res. (Epub ahead of print) (2016)
You're in the Switzerland store. Not in Switzerland? Choose your country
You're in the Switzerland store (prices in CHF, shipping to Switzerland only). Ordering from another country? Please select it below.
Please note that not all products are available in every country store. Choose your country before starting the ordering process.
Country
Switzerland
United Kingdom
France
Germany
Austria
Italy
South Korea
United States
Argentina
Australia
Belgium
Bosnia and Herzegovina
Brazil
Canada
Chile
China
Colombia
Cyprus
Czech Republic
Denmark
Ecuador
Egypt
Estonia
Finland
Greece
Hong Kong
Hungary
India
Iran
Iraq
Ireland
Israel
Japan
Latvia
Lithuania
Luxembourg
Malaysia
Mexico
Netherlands
New Zealand
Norway
Pakistan
Peru
Poland
Portugal
Romania
Russia
Singapore
Slovakia
Slovenia
South Africa
Spain
Sweden
Syria
Taiwan
Thailand
Turkey
Uruguay
Venezuela
Other Country
No country found




Download PDF








